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Sunlmal*y 
All members of the verotoxin (VT) family specifically recognize globo-series glycolipids on the 
surface of susceptible cells. Those toxins  that are associated with human disease, VT1,  VT2, 
and VT2c, bind to globotriaosyl ceramide (Gb3) while VT2e, which is associated with edema 
disease of swine, binds preferentially to globotetraosyl  ceramide (Gb4). We were recently able 
to identify, using site-directed mutagenesis, amino acids in the binding subunit of these toxins 
that are important in defining their glycosphingolipid  (GSL) binding specificity (Tyrrell, G. J., 
K. Ramotar, B. Boyd, B. W. Toye, C. A. Lingwood, and J. L. Brunton. 1992. Proc. Natl. Acad. 
Sci. USA. 89:524). The concomitant mutation of Gln64 and Lys66 in the VT2e binding subunit 
to the corresponding residues (Glu and Gin, respectively) found in VT2 effectively converted 
the GSL binding specificity of the mutant toxin from Gb4 to Gb3 in vitro. We now report that 
the altered carbohydrate recognition of the mutant toxin (termed GT3) has biological significance, 
resulting in a unique disease after intravascular injection into pigs as compared with classical 
VT2e-induced edema disease. The tissue localization of radiolabeled GT3 after intravascular  injection 
was elevated in neural tissues compared with VT2e accumulation, while localization  of GT3 
to the gastrointestinal  tract was relatively reduced. Accordingly, the pathological lesions after 
challenge with GT3 involved gross edema of the cerebrum, cerebellum, and brain stem, while 
purified VT2e caused hemorrhage and edema of the cerebellum, and submucosa of the stomach 
and large intestine. In addition, both radiolabeled toxins bound extensively to tissues not directly 
involved in the pathology of disease. VT2e, unlike GT3 or VT1, bound extensively to red cells, 
which have high levels of Gb4. The overall tissue distribution of VT2e was thus found to be 
influenced by regional blood flow to each organ and not solely by the GB4 levels of these tissues. 
Conversely, the distribution of GT3 (and VT1), which cleared more rapidly from the circulation, 
correlated with respective tissue Gb3 levels rather than blood flow. These studies indicate the 
primary role of carbohydrate binding specificity in determining systemic pathology, suggest that 
the red cells act as a toxin carrier in edema disease, and indicate that red cell binding does not 
protect against  the pathology of systemic verotoxemia. 
1  "~ [erotoxins (VTs) are a unique family of Escherichia toll- 
elaborated  subunit toxins  that recognize globo-series 
glycolipids on the surface of susceptible cells (1-4). Certain 
1 Abbreviations  used  in  this  paper: Gb3, globotriaosyl  ceramide; Gb4, 
globotetraosyl ceramide; Gbs, galactosylglobotetraosyl ceramide; GSL, 
glycosphingolipid; HUS, hemolytic uremic syndrome; VT, verotoxin. 
serotypes of VT-producing E. coli (VTEC), most notably 
O157:H7,  are strongly associated with hemorrhagic colitis 
and hemolytic uremic syndrome (5, 6). The pathogenesis of 
these infections, however, is poorly understood. The edema 
This was presented at the American Society for Microbiology General 
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for the pig. This toxin is closely related to VT2 (Shiga-like 
toxin II [SLT II]) and has therefore also been termed SLT 
IIv (variant)  (7).  A  recent consensus on nomenclature has 
agreed to the term VT2e or SLT IIe (8). This toxin is respon- 
sible for a disease  in pigs typified  by edema, perivascular hemor- 
rhage, and necrosis  of small blood vessels (9).  The lesions 
are primarily restricted to the gastric and colonic submucosa, 
the colonic mesentery, the eyelids, and cerebellar folia. Un- 
like other members of the VT family, which bind solely to 
globotriaosyl ceramide (Gb3), VT2e is able to bind to globo- 
tetraosyl ceramide (Gb4) in the solid phase (3,  4). 
Based on the close homology of VT2 and VT2e and the 
lesser degree of homology between VT2 and VT1 in the B 
subunit, we have used site-directed mutagenesis to define amino 
acids in the B subunit responsible,  at least in part, for the 
discrimination of binding of Gb3 and Gb4 (10). Thus, con- 
comitant alteration of amino acids Gln64 and Lys66 in VT2e 
to the corresponding Glu and Gin found in VT2 renders the 
resulting mutant toxin (termed GT3) unable to recognize 
Gb4 and only bind Gb3 in a manner similar to VT1  (10). 
It is likely that this alteration in glycosphingolipid (GSL) 
binding is due to the direct interaction of these amino acid 
residues with the receptor: the recently determined crystal 
structure of the VT1  B  subunit places  the corresponding 
residues in a solvent-exposed deft that is proposed to be the 
carbohydrate-binding domain (11). Thus, the mutant toxin 
provides  an excellent  tool for examining the role of pro- 
tein-glycosphingolipid interactions in toxin-induced path- 
ology. Compared with VT2e, the mutant GT3 was found 
to show an altered cytotoxic specificity for cells in culture, 
typified by VT1, which correlated with their GSL content 
(10). We now report on the tissue localization and pathology 
of this mutant toxin in comparison with the wild-type VT2e 
and VT1  after intravascular  injection into pigs. 
Materials and Methods 
Reagents.  VT1,  VT2e, and the mutant toxin GT3 were purified 
as described previously (10, 12). Carrier-free NanSI was purchased 
from  Amersham Corp.  (Arlington  Heights,  IL).  57Co micro- 
spheres (15-/~m diameter) were obtained from DuPont Co.-New 
England Nuclear (Wilmington, DE). Iodogen and Iodobeads  were 
from Pierce  Chemical  Co. (Rockford, IL). Plastic-backed  Sil-G  silica 
TIC plates were obtained from Brinkmann Instruments  (West- 
bury, NY). Horseradish  peroxidase-conjugated  goat anti-rabbit IgG 
was purchased from Sigma Chemical Co. (St. Louis, MO). 
Glycolipid Extraction and Quantitation.  Weanling  Yorkshire pigs 
(12-16 kg) were anesthetized with pentobarbitol (35 mg/kg) and 
killed by exsanguination. Representative tissue samples were col- 
lected and neutral glycolipids  were isolated as previously  described 
(13). The Gb3 and Gb4 levels in each tissue sample were quanti- 
tated by benzoylation and HPLC analysis (13). 
Toxin Radiolabeling.  VT2e  and GT3 were radiolabeled  with 12sI 
using Iodogen (10). VT1 was iodinated using Iodobeads as previ- 
ously described (14). 
Toxin Binding to Tissue Glycolipids In Vitro.  Glycolipid  extracts 
(20 mg tissue equivalent) were applied to silica  plastic-backed  TLC 
plates  and  separated in  chloroform/methanol/water  (65:25:4 
[vol/vol/vol]). Gb3 and Gb4 present in the extracts were identified 
by comparison with standards purified from human kidney (13). 
Total glycolipids  were visualized  using orcinol spray. Toxin  binding 
to individual glycolipids was determined by TLC overlay proce- 
dure (15). Polyclonal  rabbit antiserum prepared against VT2c (16) 
was used to detect VT2e and GT3 binding. Toxin binding was 
visualized using peroxidase-conjugated  goat anti-rabbit  IgG fol- 
lowed by development with 4-chloro-l-naphthol peroxidase sub- 
strate. 
Measurement of Radiolabeled Toxin or Microsphere Distribution in 
Pigs.  To determine the sites of localization of toxin in vivo, pigs 
were anesthetized with pentobarbitol (35 mg/kg) and injected via 
the ear vein with purified, iodinated toxin. In an initial experiment 
one pig each was injected with VT2e and GT3 (200/xg in 3 ml 
of PBS; sp act, 5  x  104 cpm//~g). After 2 h, the animals were 
killed by anesthetic overdose, the various tissues  were weighed, and 
the radioactivity of representative samples was determined. Due 
to the significant  binding of  VT2e to red cells, the experiment was 
repeated, including 12sI-VT1 for comparison, with the exception 
that the pigs were killed by exsanguination. In the case of each 
toxin, the amount localized to each organ was determined by ex- 
trapolating to the total organ weight. 
It was of importance to determine whether toxin distribution 
was influenced by blood flow to various tissue sites. Blood flow 
measurements  were conducted  in the laboratory  of  Dr. H, M. Clarke 
(Department of Surgical  Research, Hospital  for Sick Children). Two 
pigs were anesthetized  with Pentobarbitol (35 mg/kg) and injected 
with STCo-labeled microspheres via the left ventricle (3.3  x  107 
and 6.4  x  107 cpm, respectively). After 2 min, at which time the 
microspheres were trapped in the capillary  beds, the pigs were killed 
by anesthetic overdose. Tissues were collected for weight and ra- 
dioactivity determinations as described above for toxin distribu- 
tion measurements.  The blood flow (ml/min/100 g) to each organ 
was then calculated (17). 
Glycolipid Reconstitution of Toxin Receptor-negative Cultured Cells. 
The generation of a mutant Daudi lymphoma cell line deficient 
in Gb3 and Gb4 has been previously  described (18). Briefly, a Daudi 
cell line selected for resistance to growth inhibition by IFN-ce (19) 
was found to be deficient in Gb3 and crossresistant to verotoxin 
(18). The cell line was mutagenized and then further selected for 
resistance to 500 ng/ml verotoxin. The resulting cell line (termed 
VTs00) was found to have a greatly reduced Gb3 content (>95%) 
relative to wild-type cells. 
VTs00 cells were reconstituted with Gb3 or Gb4 by liposome- 
mediated delivery  as previously  described (20). After glycolipid in- 
corporation,  the  cells were washed, cultured  overnight,  and 
resuspended in media with or without VT2e or GT3 (100 ng/ml). 
The ceils were maintained at 37~  5% CO2 for 4 d, at which 
time the percentage of viable cells in each group was determined 
by dye exclusion. 
Determination of  the Clinical and Gross Pathological  Effects of VT2e, 
GT3, and VTI in Pigs.  Weanling pigs were injected via the ear 
vein with 24 ng/kg of VT1 or VT2e (four animals each) or in- 
creasing doses of GT3 (two animals received 12 ng/kg, while four 
animals each received  24 or 48 ng/kg body weight). The pigs were 
then observed for clinical signs of toxemia (9). Animals that began 
to experience debilitating illness were killed, while those that re- 
covered from initial signs of verotoxemia and became asymptom- 
atic were killed from 3 to 7 d postinjection. Clinical symptoms 
were classified  into three groups: nervous disorders (including in- 
coordination, confusion, inappatence,  limb paralysis, and tremors), 
edema of the eyelids and forehead, and respiratory di~culties.  A 
postmortem examination was performed on all animals immedi- 
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described previously  to determine  the gross and histopathological 
effects of each toxin (9). 
Resulm 
Gb3 but Not Gb+ Is a Functional  Receptor  for GT3.  Binding 
kinetics performed in vitro have indicated that wild-type VT2e 
binds predominantly to Gb4 and to a lesser extent to Gb3. 
In  contrast,  mutant  GT3  shows  a  selective loss  of Gb4 
binding  and increase in  Gb3 binding afhnity (10). These 
findings were reflected in vitro,  as the Gb3/Gb4 content of 
several cell lines determined the relative cytotoxicity of VT2e 
and  GT3  (10). However,  a  cell line  expressing  Gb4  but 
lacking Gb3 was not available. To confirm that Gb4 showed 
no residual functional receptor activity for GT3, we used a 
previously described technique for delivering individual GSLs 
to viable cells (20). The mutant Daudi cell line (VT~) lacks 
Gb3 (and Gb4) and is resistant to VT1 (18). As expected, the 
ceUs were found to be crossresistant to VT2e and GT3 (Fig. 
1). We have previously shown that reconstitution of cells with 
Gb3 but not with Gb+ restored VT1 sensitivity (20). Recon- 
stitution of VT500 cells with Gb3 or Gb4 induced sensitivity 
to VT2e (Fig. 1). However, induction of GT3 toxicity was 
only achieved by reconstitution with Gb3 (Fig. 1).  These 
results  demonstrate that Gb4 cannot serve as a functional 
receptor for GT3, and thus, this allowed the unambiguous 
assessment of the role of Gb4 binding in the pathology of 
pig edema disease. 
Tissue  Distribution  of  Radiolabeled Toxin.  The  most 
significant observation with regard to the tissue distribution 
of VT2e after intravenous administration  was the extensive 
binding observed to blood cells. 2 h after administration  of 
radiolabeled toxin, 30% of  VT2e was still circulating, bound 
to red cells (Fig. 2). This is entirely unlike previous experi- 
ments with VT1 distribution in rabbits, which showed rapid 
clearance of toxin from the circulation and accumulation in 
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Figure  1.  Demonstration of the functional receptor specificity of wild- 
type VT2e and mutant GT3. The ability of Gb3 and Gb4 to act as func- 
tional receptors for VT2e and GT3 was examined using a glycolipid-deficient 
mutant Daudi cell line. VTs00 cells were reconstituted  with either Gb3 
or Gb4 by liposome-mediated  delivery (20) and then incubated  in media 
containing 100 ng/ml VT2e or GT3. Reconstituted cells that were in- 
cubated  in media alone served as controls (zero cell death).  Cell viability 
was  assayed after  4 d. 
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Figure 2.  Tissue binding distribution ofradiolabeled  VT2e, GT3, and 
VT1. tzSI-labeled  verotoxins were individually injected via the ear vein into 
weanling pigs and allowed to circulate for 2 h. At this time the animals 
were killed by exsanguination  and the various tissues were weighed and 
a portion subjected to gamma counting. 
target organs (central nervous system [CNS] and cecum) (21). 
These experiments were therefore repeated in comparison with 
VT1, and in a manner similar to the rabbit model, binding 
of VT1 to pig red cells is minimal (Fig. 2). To compare the 
toxin dose delivered to various tissues, the distributions  of 
VT2e, GT3, and VT1 were normalized for tissue weight (Fig. 
3). Significant differences between the localization  of GT3 
and the wild-type VT2e were the reduced binding for GT3 
observed in the gastrointestinal  tract (Fig. 3 A) and the in- 
creased binding of GT3 relative to VT2e for neural tissues 
(brain stem, cerebellum,  and cerebrum; Fig. 3 B). All the 
differences observed for the tissue localization of GT3 as op- 
posed to VT2e were duplicated for VT1 localization  (Fig. 
3). Thus, the tissue distribution correlated with the restricted 
binding specificity of GT3 and VT1  for Gb3 as compared 
to Gb3 and Gb4 for VT2e. 
Exsanguination  had no effect on the relative distribution 
of VT2e and GT3 for all organs examined with the excep- 
tion of the spleen. In this case, exsanguination before tissue 
collection reduced the amount of VT2e bound (by fourfold) 
to levels observed for GT3 and VT1. Results from the latter 
experiment, in which animals were exsanguinated  before tissue 
collection,  are presented  here. 
Quantitation of Tissue Levels of Gbs and Gb4.  Total Gb3 
and Gb4 levels for each tissue were quantitated by HPLC (13) 
(Table 1).  Tissue localization of VT1 and GT3 was found 
to  correlate  directly with  the level of Gb3  in  the target 
tissues (R  2 =  0.68 and 0.81, respectively; Fig. 4 A). Tissue 
localization  of VT2e,  however, did not correlate with the 
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Figure 3.  Comparison  of toxin binding  normalized  for tissue weight. 
To compare the relative  binding of VT2e, GT3, or VT1 to each organ, 
the toxin distribution was normalized  for tissue weight. The data have 
been organized  according  to the sites that show  pathology  after  challenge 
with purified  VT2e (9) (21) gastrointestinal  tract; (/3) central  nervous  system. 
Toxin binding to other tissues is shown in C. 
tissue levels of Gb4 or Gb4  +  Gb3 (R 2 =  0.21 for both; Fig. 
4 B). 
Binding of VT2e and GT3 to Glycolipids Extracted from Pig 
Tissues.  Binding of VT2e and GT3 to lipids extracted from 
pig tissues was performed to determine whether other toxin- 
binding GSL species were present.  It has been shown that 
in addition to Gb3 and Gb4,  VT2e recognizes galactosyl- 
globotetraosyl ceramide (Gbs) (4). As shown in Fig. 5, GT3 
bound only to Gb3 in tissue extracts while VT2e recognized 
Gb3 and Gb4. Gbs was not detected in the lipid extracts of 
the tissues  examined (Fig.  5). 
Table  1.  Concentration  of Gb3 and Gb4 in Pig Tissues 
Tissue  Gb3  Gb4 
nmol/g  nmol/g 
Liver  11.1  ND 
Heart  23.7  43.5 
Lung  38.0  27.2 
Spleen  89.7  138.4 
Kidney medulla  20.2  52.5 
Kidney cortex  18.0  13.9 
Stomach fundus  14.1  14.3 
Stomach antrum  13.6  10.9 
Red cells*  0.70  18.0 
Eyelid  14.2  32.2 
Colon  21.9  18.8 
Colon mesentery  25.4  18.5 
Cerebrum  ND  ND 
Cerebellum  ND  ND 
* nmol GSL/ml blood. 
The Localization of VT2e but Not of GT3 or VT1 Is Influenced 
by Differential Tissue Blood Flow,  Gb3 and/or Gb4 were de- 
tected at some level in all tissues examined, yet the accumula- 
tion of VT2e generally did not correlate with the glycolipid 
levels observed.  Since VT2e bound extensively to red cells, 
we considered whether differential blood flow to various 
organs could be a factor affecting toxin distribution. The 
cardiac output and blood flow to various tissues were deter- 
mined in two pigs using the radiolabeled microsphere tech- 
nique (17). VT2e, but not VT1 or GT3, distribution was 
found to be related to blood flow (Fig. 6). When the tissue 
localization data was replotted allowing for blood flow (Fig. 
7), it was apparent that the eyelids  bound a significantly greater 
fraction of available toxin than other tissues. It was now evi- 
dent that the specific binding to the stomach fundus was 
greater relative to the antrum. Furthermore, the consider- 
able toxin binding to kidney and spleen was likely a result 
of high blood flow to these sites. 
In Vivo Action of the Mutant Toxin Reflects Its Altered Receptor 
Specificity and Tissue Localization.  Histological and gross anal- 
ysis of the pathology induced after intravenous administra- 
tion of VT2e, GT3, and VT1 was found to segregate remark- 
ably according to the ability of the toxins to bind to Gb3 
or Gb4 (Table 2). Thus, VT1 and GT3 were found to cause 
identical lesions, particularly notable in that of brain edema; 
high doses of GT3 caused more marked, gelatinous edema 
than was observed for VT2e. In contrast, the wild-type VT2e 
caused  microangiopathic  hemorrhage  and  edema  in  the 
stomach fundus and large intestine (not seen for GT3 or VT1). 
Despite the effect of GSL-binding specificity on toxin local- 
ization and sites of pathology, the basic histological lesion 
observed was the same for all three toxins. Fig. 8 shows the 
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Figure  4.  Correlation of toxin distribution with receptor concentra- 
tion.  ml-labeled VT1, GT3, or VT2e were injected via the ear vein of 
weanling pigs and allowed to circulate for 2 h. The toxin localization to 
various tissues was determined and plotted against the total GSL content 
of that tissue determined by HPLC analysis. Neural tissues, in which Gb3 
and Gb4 were not detected, are not represented above. (/1) VT1 (I-q) (R  2 
=  0.68) and GT3 (&) (R  2 =  0.81) bound is plotted against Gb3 con- 
centration. (B) VT2e bound is plotted against Gb4 (l-q) (R  2 =  0.21) or 
Gb4  +  Gb3 concentration (&) (R  2 =  0.21). 
distinct pathology of the colonic mucosa after exposure to 
VT2e compared with the unaffected colonic histology of GT3- 
treated pigs. Significant edema of the submucosa and damage 
to the epithelium was observed only for VT2e-treated pigs 
(Fig. 8). Neither gross nor microscopic lesions were observed 
in lung,  liver,  or  spleen of pigs  to which  VT2e,  GT3,  or 
VT1 had been administered.  A  detailed histological analysis 
of lesions observed in VT2e-, GT3-,  and VTl-treated pigs 
will be presented elsewhere (Gyles et al., manuscript in prep- 
aration). 
It was interesting to note that both animals that received 
a dose of 12 ng/kg and half of those receiving 24 ng/kg of 
GT3 recovered fully from the neurological manifestations of 
toxemia (see Table 2; mean recovery time in each group was 
40 and 37 h, respectively). In the latter group, recovery was 
associated with the failure to develop respiratory difficulties 
at the clinical level. Furthermore, the pathology of CNS, eye, 
and forehead edema had  normalized at postmortem  (Table 
2). This characteristic of GT3 toxicity has not been observed 
in the case of VT2e (9)  and may relate to the fact that  al- 
Figure 5.  Binding  of  VT2e and GT3 to glycolipid  extracts  of  pig tissues 
by TIC overlay. Neutral glycolipids  were isolated from pig tissues as de- 
scribed in Materials and Methods. Glycolipid  extracts  were  applied  to plastic- 
backed TLC plates (20 mg tissue equivalent per lane, with the exception 
of  lane 7, which represents  50 #1 of  blood) and separated  (chloroform/meth- 
anol/water, 65:25:4 [vol/vol/vol]). Tissue extracts are: lane I, spleen; lane 
2, liver; lane 3, heart; lane 4, lung; lane 5, kidney cortex; lane 6, kidney 
medulla; lane 7, red blood cells; lane 8, stomach fundus; lane 9, stomach 
antrum; lane 10, colon mesentery; lane I1, colon; lane 12,  standard Gb3 
and Gb4. (A) Total glycolipid detection by orcinol spray. (B) An equiva- 
lent set of TIC plates was incubated with VT2e (0.15/~g/ml), followed 
by a cross reactive  polyclonal antisera raised against VT2c (1:1,000 dilu- 
tion). The plates  were finally  incubated  with a peroxidase-conjugated  goat 
anti-rabbit antibody,  and binding was visualized  using 4-chloro-l-naphthol 
(15). (C) Plates  were treated as in B but were incubated with GT3 instead 
of VT2e. 
though the generalized edema of the brain was more marked 
and gelatinous for GT3, hemorrhage of the cerebellar folium 
(9)  was  not  observed for GT3-treated pigs  (Table 2). 
Discussion 
The disease in pigs caused by VTs is quite distinct  from 
the hemolytic uremic syndrome (HUS) that may be observed 
in humans after infection by VT1- or VT2-producing E. coli. 
Nevertheless, the pig provides a more amenable model to study 
the molecular basis of the cytopathology, and pig edema dis- 
ease is a significant veterinary problem in its own right. Studies 
with  VT1 in the rabbit  model have shown  that  the lesion 
sites correlate with the expression of glycolipid receptors for 
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Figure  6.  Correlation of toxin distribution with regional blood flow. 
The relationship between radiolabeled toxin localization and regional blood 
flow was examined.  Blood flow measurements  were performed in two 
animals under the conditions  used in the toxin distribution studies. The 
percentage of each toxin delivered to each organ was plotted against the 
average blood flow (ml/min/100 g) to that tissue. The correlation of toxin 
distribution with blood flow was as follows: 12sI-VT1 (A, tL2  =  0.33), 
12sI-VT2e (B, R 2 =  0.64),  t25I-GT3 (C, RJ  =  0.23). 
this toxin in the rabbit tissues (21, 22). Our present studies 
more definitively illustrate the role of glycolipid binding in 
verotoxemia and allow us to draw some interesting conclusions. 
First, the tissue distribution of GT3 was distinct from that 
of VT2e. For each tissue, GT3 localized in a manner virtu- 
ally identical to VT1, which also shows a binding specificity 
restricted to Gb3. The major differences in the distribution 
of GT3/VT1 relative to VT2e included dramatically reduced 
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red cell binding, decreased binding to the gastrointestinal  tract, 
and increased binding to the CNS. These alterations  correlated 
with differences in pathology, most notably the lack of GT3- 
or VTl-induced  lesions in the colon and stomach. 
Second, GT3 and VT-1 generally distributed in vivo ac- 
cording  to  the  concentration  of Gb3  in  each  tissue.  This 
binding correlation was less marked for the TIC overlay, par- 
ticularly for GT3 binding renal glycolipids, but solid phase 
assays do not necessarily reflect glycolipid receptor function 
in vivo. However, lesions were not observed at some of the 
sites where extensive toxin binding was found. Thus, it ap- 
pears that some toxin-binding sites are relatively resistant to 
toxin action while other sites are highly sensitive.  The same 
might be true in the case of humans,  where Gb3 is present 
in many tissues (23), yet glomerular thrombotic microangio- 
pathy is the major lesion of HUS (24).  The nature  of the 
toxin-insensitive sites might relate to differential routing of 
bound toxin in different cells.  A  cell line was recently de- 
scribed (25) that binds and internalizes VT but that delivers 
it  to lysosomes and is thus not intoxicated.  Sensitive cells 
deliver toxin to the ER and Golgi complex (25, Khine, A. A., 
and C. A. Ling'wood, manuscript submitted for publication), 
which may reflect a specialized  role of Gb3 to target the ER 
in these cells (Khine,  A. A.,  and C.  A. Lingwood,  manu- 
script submitted for publication).  It is also of relevance to 
note that sensitivity of cultured cells to VT is a function of 
cell growth (26). We have found that stationary, in contrast 
to log-phase-cultured,  cells are resistant to verotoxin.  This 
altered sensitivity to VT was found to be a function of Gb3 
surface exposure, but not  of changes in total Gb3 content 
during the cell cycle (26). However, since the binding of VT1 
and GT3 was found to correlate with total tissue Gb3 con- 
tent, such variations may only be relevant at the level of in- 
dividual cells and not affect Gb3 availability as a whole. Our 
finding that liver and lung contain significant levels of Gb3, 
1750  Glycolipid Binding Specificity Determines Sites of Verotoxin  Pathology Table  2.  Pathological  Effects of GT3,  VTee,  and VT1  in Pigs 
Clinical symptoms 
Nervous  Respiratory  Postmortem edema (n) 
disorders  Edema  difficulties  Recovery 
Avg.  time  from  Eye/  Large 
Toxin  Dose*  n  to  onset  n  *Severity  n  Severity  n  Severity  symptoms  CNS  forehead  Stomach  intestine 
 /kg  h 
GT3  12  2  17  2  ++++  0  0  Yes  (2/2)  0  0  0  0 
24  4  14  4  ++++  2  ++  2  ++  Yes  (2/4)s  211  2  0  0 
48  4  8  4  ++++  4  ++++  4  ++++  No  4  4  0  0 
VTE  24  4  7  4  ++++  4  ++  4  +++  No  4  4  4  4 
VT1  24  4  8  4  ++++  0  4  ++  No  4  4  0  0 
* All animals received the indicated  dose of toxin by intravenous injection via the ear vein. 
* Number of animals affected. The severity of symptoms was similar for affected animals at each dose and is scored from mild ( + ) to severe ( + + + + ) 
in each case. 
S Two of four of the pigs that received 24 ng/kg of GT3 did not develop respiratory difficulties or edema and fully recovered from their symptoms 
within 48 h postinjection. 
rl Marked  gelatinous  edema of the CNS with GT3. More watery fluid with VT2e as well as extensive hemorrhage  of the cerebellar folia. 
Figure 8.  Comparison of microscopic appearance of the colon of pigs inoculated with 24 ng/kg GT3 (A) or VT2e (B). (A) The colon of pigs 
inoculated with GT3 appeared essentially normal; the epithelium (E) is intact and the submucosa (S) is not distended. (B) The colon of pigs inoculated 
with VT2e showed loss of epithelial covering (E) and marked edema of the submucosa (S), causing an increase in thickness of the intestine (hematoxylin- 
eosin stain;  x 73). 
1751  Boyd et al. bind VT1 and GT3 (and VT2e to a lesser extent),  and yet 
show no evidence of lesions illustrates the considerable gap 
in our understanding  of Gb3-related pathology of VTs. 
Third, pig red cells bind significant levels of VT2e yet do 
not  protect  animals  from  toxin-induced  pathology.  The 
prolonged retention of VT2e in the circulation may actually 
be a risk factor, as susceptible tissues may effectively be sub- 
jected to prolonged toxin exposure as compared with GT3, 
which rapidly dears from the circulation. It has recently been 
proposed that humans with lower levels of red cell-associated 
Gb3 and P1 antigen may be at increased risk for developing 
HUS during  VTEC  infection  (27).  The Pl glycolipid has 
a terminal Galc~l-4Gal dissacharide required for VT binding 
and is present on the red cells of most humans  (27). How- 
ever, our results indicate that the ability of red cells to bind 
VT is not protective in pigs. The same may be true in humans. 
It is possible that  glycolipid content  of human  red cells  is 
indicative of GSL levels in other tissues, some of which may 
be resistant  to toxin action and thus reduce the toxin load 
to sensitive sites. 
Unlike VT1 and GT3, the distribution of VT2e was not 
a function  of its receptor distribution  but rather  of blood 
flow. This may indicate that the administered dose was un- 
able to saturate the initial  target  (red blood cells)  and that 
the observed tissue distribution was a result of red blood cell 
delivery and a slower toxin exchange from this carrier to target 
organ receptors.  When the normalization  factor for blood 
flow was included in the calculation of distribution,  it be- 
came obvious that  the eyelids  bound a considerably larger 
fraction of the blood-delivered VT2e toxin than other tissues. 
This indicates that this tissue has a higher affinity for VT2e, 
perhaps due to increased receptor exposure. This correlates 
with the observation that the eyelids are one of the primary 
and earliest  sites  of VT2e-induced lesions in pigs (9). 
Although  the  gross  tissue levels  of Gb3 correlated well 
with GT3 and VT1 localization,  toxin binding is really in- 
dicative of vascular GSL content. Thus, the negative correla- 
tion of VT2e distribution with total organ Gb4 levels may 
merely reflect the nonvascular distribution of Gb4 in various 
tissues. 
In comparing the in vivo pathogenesis of VT2e with that 
of the  mutant  GT3,  we have  shown  that  Gb4 binding  is 
necessary for the action of VT2e on gastrointestinal  tissue, 
despite the fact that  these tissues contain  significant  levels 
of both Gb3 and Gb4. GT3 showed greatly reduced binding 
and none of the morphological lesions in the colon and co- 
lonic mesentery typical of VT2e action. The surface exposure 
of Gb4 in the gastrointestinal  mucosa and vasculature must 
therefore be far greater  than  that  of Gb3.  In contrast,  the 
binding of VT2e, relative to GT3 and VT1, was reduced in 
brain tissues.  These results indicate a differential distribution 
or function of Gb3 and Gb4 in these tissues.  We were un- 
able to detect these glycolipids in pig brain lipid extracts (by 
TLC overlay or HPLC) but they may be present in high con- 
centrations in discrete blood vessels of the nervous system. 
This was found to be the case in rabbits, where intravenously 
administered VT1 was found to bind to a few specific blood 
vessels of the brain,  as detected by indirect immunofluores- 
cence (21).  However, galabiosyl ceramide could be detected 
by TLC overlay in rabbit brain (22). Nevertheless, the present 
studies establish that the glycolipid binding specificity of VTs 
is a primary determinant in the site of toxin localization and 
toxin-induced lesions in vivo. 
The lack of lesions in the gastrointestinal  tract and cere- 
bellar folia after administration of GT3 and the finding that 
at low doses all pigs recovered suggests that GT3 may repre- 
sent a viable route for the immunoprotection of pigs against 
the edema disease  toxin. 
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